The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research.

ABSTRACT:

Background

In the asymptomatic "preclinical" phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed to participants in research settings, and biomarker testing and results disclosure will be implemented in clinical settings in the future. Biomarker disclosure has potential psychosocial benefits and harms, impacting affected individuals and their support person(s). Limited data are available about with whom research participants share their results, information that will be necessary to develop disclosure protocols and post-disclosure resources. Additionally, existing research has been conducted in largely White cohorts, limiting applicability to future clinical populations.

M

SUBMITTER: Ketchum FB 

PROVIDER: S-EPMC10423755 | biostudies-literature | 2023 Jul-Sep

REPOSITORIES: biostudies-literature